LBA66 IMmotion010: Efficacy and safety from the phase III study of atezolizumab (atezo) vs placebo (pbo) as adjuvant therapy in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection

A. Bex, R. Uzzo, J.A. Karam, V.A. Master, F. Donskov, Cynthia Suárez, Laurence Albigès, B.I. Rini, Y. Tomita, A. Kann, G. Procopio, F. Massari, M. Zibelman, I. Antonyan, Mahrukh A Huseni, Devy Basu, B. Ci, W. Leung, O. Khan, S.K. Pal